Skip to main content

Table 2 Responses to immunotherapy

From: Comprehensive molecular and clinical characterization of Asian melanoma patients treated with anti-PD-1 antibody

RECIST v1.1 All treated patients (n = 152)
Best response
 Complete response 4 (3%)
 Partial response 22 (14%)
 Stable disease 66 (43%)
 Progressive disease 54 (36%)
 Not evaluable 6 (4%)
 Overall response rate 17% (95% CI, 11–22)
 Disease control rate 60% (95% CI, 52–68)
 Median time to response 2.0 months
 Median duration of response 6.2 months
\